MAM
CRVS icon

Meeder Asset Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Meeder Asset Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Buy
+754
New +$12K ﹤0.01% 678
2022
Q3 		– Sell
-1,984
Closed -$2K – 2178
2022
Q2 		$2K Buy
1,984
+1,007
+103% +$1.24K ﹤0.01% 1874
2022
Q1 		$2K Buy
+977
New +$1.79K ﹤0.01% 2023
2021
Q4 		– Sell
-645
Closed -$3K – 1426
2021
Q3 		$3K Hold
645
– – ﹤0.01% 2064
2021
Q2 		$2K Hold
645
– – ﹤0.01% 2196
2021
Q1 		$2K Buy
+645
New +$2.33K ﹤0.01% 2062
2020
Q4 		– Sell
-645
Closed -$3K – 1947
2020
Q3 		$3K Buy
645
+37
+6% +$148 ﹤0.01% 1709
2020
Q2 		$2K Hold
608
– – ﹤0.01% 1754
2020
Q1 		$1K Sell
608
-1,480
-71% -$6.01K ﹤0.01% 2173
2019
Q4 		$11K Sell
2,088
-134
-6% -$469 ﹤0.01% 1532
2019
Q3 		$7K Buy
2,222
+1,216
+121% +$5.1K ﹤0.01% 1638
2019
Q2 		$4K Buy
1,006
+711
+241% +$2.79K ﹤0.01% 1712
2019
Q1 		$1K Sell
295
-1
-0.3% -$4 ﹤0.01% 1613
2018
Q4 		$1K Sell
296
-280
-49% -$1.91K ﹤0.01% 1621
2018
Q3 		$5K Buy
+576
New +$5.76K ﹤0.01% 1321
2018
Q2 		– Sell
-108
Closed -$1K – 1579
2018
Q1 		$1K Buy
108
+10
+10% +$95 ﹤0.01% 1447
2017
Q4 		$1K Buy
98
+21
+27% +$269 ﹤0.01% 1562
2017
Q3 		$1K Sell
77
-389
-83% -$5.38K ﹤0.01% 1538
2017
Q2 		$6K Buy
466
+245
+111% +$2.62K ﹤0.01% 1135
2017
Q1 		$5K Buy
+221
New +$3.46K ﹤0.01% 1060

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Meeder Asset Management's CRVS Position: Q1 2026 in Review

Meeder Asset Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 754 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #678 among its holdings. This is a return to the name: Meeder Asset Management previously reported a position in CRVS as recently as Q2 2022.

Meeder Asset Management first reported a position in CRVS in Q1 2017 and has held it in 20 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Meeder Asset Management held 754 shares of Corvus Pharmaceuticals worth $11K as of Q1 2026.
  • Corvus Pharmaceuticals was a new Meeder Asset Management position in Q1 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #678 holding.
  • Meeder Asset Management first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 20 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.